Drug Channels
APRIL 4, 2025
Click here to see the original post from January 2025. It's time for Drug Channels annual examination of U.S. brand-name drug pricing. For 2024, average brand-name drugs list prices grew by only 2.3%. Read more 2006-2025 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company.
STAT
OCTOBER 20, 2022
A separate policy aimed at moderating price growth would make drugmakers pay back Medicare if they hike prices faster than inflation. And in 2025, Medicare beneficiaries will see their costs capped at $2,000 per year. Moreover, the process does not start until 2026.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
STAT
JULY 9, 2024
Pharma’s dwindling alliances The pharmaceutical industry didn’t have many friends that stuck up for it when Democrats passed a historic drug pricing law in 2022. By the beginning of 2025, even many of the industry’s remaining allies will have left Congress, Rachel Cohrs Zhang reports.
Proxsys Rx
APRIL 1, 2025
The situation may worsen if more drug companies follow suit in restricting 340B savings. As we enter 2025 Q2, the sad truth is that most 340B hospitals are struggling to protect their programs from further prescription-savings erosion. The Expanding Challenges of 340B in 2025 1.
STAT
JULY 9, 2024
Moreover, the FTC found the prescription drug market is “highly concentrated” because the largest PBMs are owned by insurers and, in turn, own specialty, mail order or retail pharmacies.
STAT
MAY 1, 2023
But revised legislation prepared for a Tuesday markup by the Senate health committee shows that the changes would now take effect 30 months after the law is passed, no sooner than November 2025. The original date that pharmacy benefit manager reforms were supposed to take effect was Jan.
STAT
AUGUST 30, 2023
government’s initial approach to negotiating drug prices could discourage cheaper biosimilar versions of more complex pharmaceuticals that eat up a high portion of total Medicare spending , Bloomberg Law explains. Amgen and J&J reached an agreement in May to allow a biosimilar for Stelara no later than Jan.
Expert insights. Personalized for you.
52 
Let's personalize your content